OS Therapies grants Craig Eagle 300,000 stock options
The options vest monthly over 12 installments, conditioned on continued service as a director at each vesting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OS Therapies Inc (OSTX) director Craig Eagle received a grant of options to purchase 300,000 shares of common stock on October 22, 2026, with an exercise price of $1.25 per share; the options expire October 22, 2036. They vest in 12 equal installments on each monthly anniversary of the grant date, provided he is serving as a director on each applicable vesting date. The grant was made under the company's amended and restated 2023 incentive compensation plan and a stock option award agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock options (right to buy) F1 | 300,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.
Key Figures
Key Terms
stock option award agreement financial
incentive compensation plan financial
vesting date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did OS Therapies (OSTX) director Craig Eagle receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.